Buprenorphine Screen with Reflex, Random, Urine
Use
This test is useful for screening and confirmation of drug abuse or use of buprenorphine. It begins with a screening immunoassay; if positive, a confirmation by liquid chromatography–tandem mass spectrometry is performed. The immunoassay has a screening cutoff of 5 ng/mL for buprenorphine and confirmation is triggered for buprenorphine ≥ 5 ng/mL or norbuprenorphine ≥ 2.5 ng/mL, supporting detection of recent use. It helps monitor compliance, detect misuse, or confirm therapeutic exposure consistent with substitution therapy or analgesic use.
Special Instructions
Not provided.
Limitations
Immunoassay screens can produce false-positive or false-negative results due to cross-reactivity with unrelated substances or interfering compounds. Results may be influenced by factors such as fluid intake or specimen integrity. Submitting less than the required volume may compromise testing. Interpretation should consider possible interferences, and confirmation by LC‑MS/MS is required for positive screens.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 93494-3 - Buprenorphine Ur Ql Scn
- 93494-3 - Buprenorphine Ur Ql Scn
Result Turnaround Time
0-2 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
5 mL
Minimum Volume
2.5 mL
Container
Plastic urine container for collection; plastic vial for submission
Collection Instructions
Collect a random urine specimen; submit 5 mL in one plastic vial; no preservative.
Causes for Rejection
No preservative; all specimens evaluated for suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient, 72 hours |
| Refrigerated | Refrigerated, 14 days |
| Frozen | Frozen, 14 days |